3.14
0.64%
0.02
前日終値:
$3.12
開ける:
$3.13
24時間の取引高:
309.28K
Relative Volume:
2.00
時価総額:
$84.95M
収益:
$1.04M
当期純損益:
$-32.07M
株価収益率:
-0.4869
EPS:
-6.4491
ネットキャッシュフロー:
$-26.12M
1週間 パフォーマンス:
+0.96%
1か月 パフォーマンス:
+6.80%
6か月 パフォーマンス:
-29.44%
1年 パフォーマンス:
+1.95%
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
名前
Vistagen Therapeutics Inc
セクター
電話
650-577-3600
住所
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2022-07-22 | ダウングレード | Jefferies | Buy → Hold |
2022-07-22 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2022-07-22 | ダウングレード | William Blair | Outperform → Mkt Perform |
2021-05-20 | 開始されました | Robert W. Baird | Outperform |
2021-02-18 | 開始されました | Jefferies | Buy |
2021-01-04 | アップグレード | William Blair | Mkt Perform → Outperform |
2018-06-27 | 開始されました | Maxim Group | Buy |
2018-02-08 | 繰り返されました | Chardan Capital Markets | Buy |
2017-03-28 | 開始されました | Maxim Group | Buy |
すべてを表示
Vistagen Therapeutics Inc (VTGN) 最新ニュース
Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlight - GuruFocus.com
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... - Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... By GuruFocus - Investing.com Canada
Vistagen Therapeutics Reports Increased R&D Expenses - TipRanks
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Vistagen Therapeutics Inc Reports Q2 2025 Revenue of $183,000, M - GuruFocus.com
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update - StockTitan
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect - GuruFocus.com
Vistagen to Present at the 2024 Neuroscience Education Institute Congress - Business Wire
Vistagen Therapeutics (VTGN) Scheduled to Post Earnings on Thursday - MarketBeat
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 - sharewise
VTGN (Vistagen Therapeutics) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder - Seeking Alpha
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know - MSN
Mental Disorder Treatment Market Global Industry Forecast - openPR
Vistagen, The Goldie Hawn Foundation, and MindUP students Rings the Nasdaq Stock Market Closing Bell on World Mental Health Day - Nasdaq
Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance UK
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day - sharewise
Great Point Partners LLC Has $5.32 Million Stock Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Vistagen enrols first subject in Phase III trial of social anxiety disorder drug - Yahoo Finance
Vistagen advances phase 3 trial for social anxiety treatment By Investing.com - Investing.com Australia
Vistagen advances phase 3 trial for social anxiety treatment - Investing.com
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - StockTitan
All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy - Benzinga
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy - Yahoo Finance
Mental Disorder Treatment Market Expected to Expand at a Steady - openPR
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average of $3.52 - MarketBeat
Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50 Day Moving Average of $3.52 - Defense World
Mental Disorder Treatment Market Detailed In New Research - openPR
Vistagen shareholders approve board nominees and executive pay By Investing.com - Investing.com Canada
Vistagen shareholders approve board nominees and executive pay - Investing.com
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving Average of $3.49 - Defense World
Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above 50 Day Moving Average of $3.49 - MarketBeat
The Globe and Mail - The Globe and Mail
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates - MSN
VTGN (Vistagen Therapeutics) 3-Year Revenue Growth Rate : -47.50% (As of Jun. 2024) - GuruFocus.com
VTGN (Vistagen Therapeutics) Enterprise Value : $-17.63 Mil (As of Aug. 19, 2024) - GuruFocus.com
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) to Post Q2 2025 Earnings of ($0.39) Per Share, William Blair Forecasts - Defense World
VTGN (Vistagen Therapeutics) Cash-to-Debt : 54.45 (As of Jun. 2024) - GuruFocus.com
Q2 2025 EPS Estimates for Vistagen Therapeutics, Inc. Lifted by Analyst (NASDAQ:VTGN) - MarketBeat
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2025 Earnings Call Transcript - Insider Monkey
Vanguard Group Inc. Sells 41,346 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Earnings call: Vistagen advances in Phase 3 trials for SAD treatment - Investing.com Canada
VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025 - InvestorPlace
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update - wallstreet:online
Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday - Defense World
Vistagen Therapeutics (VTGN) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Vistagen Therapeutics Inc (VTGN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):